120 related articles for article (PubMed ID: 15906185)
1. American Association for Cancer Research--96th Annual Meeting. Growth factor receptors.
Phillips T; Collins T; Davies J
IDrugs; 2005 Jun; 8(6):454-7. PubMed ID: 15906185
[No Abstract] [Full Text] [Related]
2. The role of new agents in the treatment of colorectal cancer.
Ruiz de Erenchun F
Oncology; 2005; 68(2-3):162; author reply 162. PubMed ID: 16097096
[No Abstract] [Full Text] [Related]
3. Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over?
Carbognin L; Pilotto S; Peretti U; Tortora G; Bria E
Expert Opin Investig Drugs; 2016 Jun; 25(6):635-8. PubMed ID: 27054716
[No Abstract] [Full Text] [Related]
4. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
5. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice.
Blaskovich MA; Lin Q; Delarue FL; Sun J; Park HS; Coppola D; Hamilton AD; Sebti SM
Nat Biotechnol; 2000 Oct; 18(10):1065-70. PubMed ID: 11017044
[TBL] [Abstract][Full Text] [Related]
6. American Association for Cancer Research--97th Annual Meeting.
Kneller S; Yager N
IDrugs; 2006 May; 9(5):334-7. PubMed ID: 16676267
[No Abstract] [Full Text] [Related]
7. Three molecularly targeted drugs tested in kidney cancer clinical trials.
Tuma RS
J Natl Cancer Inst; 2004 Sep; 96(17):1270-1. PubMed ID: 15339961
[No Abstract] [Full Text] [Related]
8. American Association for Cancer Research--100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA.
Mitra AP
IDrugs; 2009 Jun; 12(6):339-41. PubMed ID: 19517310
[No Abstract] [Full Text] [Related]
9. Anticancer therapy with angiogenesis inhibitors.
Ghilardi C; Bani MR; Giavazzi R
Tumori; 2001; 87(6):S14-6. PubMed ID: 11989610
[No Abstract] [Full Text] [Related]
10. Antiangiogenic therapy in the management of brain tumors: a clinical overview.
Kunnakkat S; Mathew M; Narayana A
Cancer Chemother Pharmacol; 2012 Sep; 70(3):353-63. PubMed ID: 22825032
[TBL] [Abstract][Full Text] [Related]
11. [Molecular targets in colon cancer].
Borner MM
Ther Umsch; 2006 Apr; 63(4):243-8. PubMed ID: 16689454
[TBL] [Abstract][Full Text] [Related]
12. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
13. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
Ellis PM; Al-Saleh K
Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
[TBL] [Abstract][Full Text] [Related]
14. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
[TBL] [Abstract][Full Text] [Related]
15. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Markman M
Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
18. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
19. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
20. [Medical chemistry and molecular mechanisms of tyrosine kinase inhibitors. The viewpoint of pharmaceutical research].
Holm M; Lehmann F; Laufer S
Pharm Unserer Zeit; 2008; 37(5):382-92. PubMed ID: 18729263
[No Abstract] [Full Text] [Related]
[Next] [New Search]
